What could a pharmaceutical marketer possibly learn from someone who spent years convincing people to download and engage with mobile games? Quite a lot, as it turns out. Genentech performance marketing engagement lead Tiffany William moved into pharma after six years in mobile gaming marketing, bringing a different approach to experimentation, data, and optimization. Her career shift raises an important question for pharma marketers focused on performance: Which lessons from gaming can improve healthcare engagement without importing tactics that do not belong anywhere near patient decisions? For anyone exploring pharma performance marketing, her experience offers a useful look at what healthcare can borrow and what it should leave behind.
Table of Contents
- Why Gaming Offers Pharma a Useful Marketing Model
- Rapid Experimentation Without Reckless Experimentation
- Segmentation and Creative Optimization in Pharma
- Where Gaming Tactics Cross the Ethical Line
- Building a Better Pharma Performance Marketing Culture
- Conclusion
- Frequently Asked Questions
Why Gaming Offers Pharma a Useful Marketing Model
Mobile gaming companies operate in an environment where almost everything can be measured. Marketers monitor acquisition, engagement, retention, creative performance, and user behavior, then quickly adjust campaigns.
William brought that background to Genentech after leaving game developer Kabam in late 2025. According to Fierce Pharma, she now works across Genentech’s portfolio to connect brand learnings and encourage marketers to use performance data more confidently.
That mindset matters because pharma marketing teams can sometimes get trapped in long campaign cycles. Teams develop a campaign, launch it, review results months later, and then prepare another large campaign.
Gaming works differently. Marketers constantly ask what happened, why it happened, and what they should test next.
However, pharma cannot simply copy gaming’s speed. Healthcare communications carry greater responsibilities, and prescription drug promotion operates under regulatory requirements that consumer gaming does not face.
Still, the underlying discipline is valuable. Instead of treating a campaign as a finished product, pharma marketers can treat appropriate digital experiences as systems that improve through evidence.
Rapid Experimentation Without Reckless Experimentation
William describes one lesson from gaming as a “fail fast, learn fast” mentality. In healthcare, that phrase requires careful interpretation.
It should never mean publishing questionable claims and correcting them later. Instead, pharma teams can apply performance marketing principles within approved boundaries.
For example, marketers can test calls to action, educational content formats, landing-page structures, channel mixes, audience journeys, and approved creative variations. They can then examine which approach helps an intended audience find useful information more easily.
Furthermore, teams can establish the hypothesis and success metric before a test begins. That simple step prevents marketers from searching through data afterward for a convenient success story.
Small experiments can also reduce wasted spending. Rather than committing a large media budget to one creative assumption, marketers can identify stronger approaches earlier and scale responsibly.
The goal is not speed for its own sake. Instead, the goal is faster learning.
This approach also changes how teams think about unsuccessful tests. A test that disproves an assumption can still create value because the next decision becomes better informed.
Segmentation and Creative Optimization in Pharma
Gaming companies rarely treat every player as identical. They examine behavior and design different experiences around meaningful audience signals.
Pharma can borrow that discipline, but it needs stronger privacy, compliance, and ethical guardrails.
Behavioral insights can help marketers understand whether healthcare professionals want clinical information, whether patients struggle to navigate educational resources, or whether certain content fails to answer common questions.
Therefore, segmentation should make communication more relevant rather than more manipulative.
Creative iteration offers another opportunity. Instead of endlessly debating which approved headline or educational approach might perform best, teams can establish responsible tests and allow evidence to guide future decisions.
This is where performance-driven pharma marketing becomes about much more than buying digital media. It creates a feedback loop between audience needs, creative decisions, media investment, and measurable outcomes.
The approach can also complement broader discussions around performance-based pharmaceutical advertising. Yet measurement alone is never enough. Marketers must also understand where traffic comes from, how messages appear, and whether partners operate within appropriate standards.
Ultimately, a high conversion rate means little if the experience producing it undermines trust.
Where Gaming Tactics Cross the Ethical Line
Gaming has another side that pharma should leave behind.
Some games are deliberately designed around urgency, rewards, streaks, scarcity, repeated prompts, and other mechanics intended to keep users engaged. Those techniques may increase time spent inside an entertainment product. However, applying similar pressure to health decisions creates serious ethical concerns.
Patients are not players, and prescriptions are not in-app purchases.
For instance, a pharmaceutical campaign should not manufacture urgency simply to push someone toward requesting a specific treatment. Likewise, marketers should be cautious about reward loops or behavioral targeting that exploits fear, anxiety, or vulnerability.
Regulatory expectations provide another clear boundary. The FDA Office of Prescription Drug Promotion works to ensure prescription drug promotion is truthful, balanced, and accurately communicated. The agency also identifies internet and social media promotion as part of the promotional landscape it oversees.
Consequently, optimization cannot become an excuse to downplay risks because benefit-heavy creative earns more clicks. Nor should an algorithm quietly optimize toward increasingly aggressive claims.
The better lesson from gaming is the experimentation infrastructure, not every engagement mechanic.
Building a Better Pharma Performance Marketing Culture
The biggest lesson may have little to do with technology.
William’s work at Genentech focuses partly on creating a culture where marketers become more comfortable asking questions, using data, and testing assumptions. She has described conducting frequent office hours as well as workshops and incubators to help marketers develop those skills.
That approach can help pharma organizations avoid another common problem: keeping performance expertise inside a specialized analytics team.
Instead, brand teams, media specialists, creative partners, compliance professionals, and analysts can share a common experimentation framework. Everyone should understand the hypothesis, measurement plan, regulatory boundaries, and learning objective.
Moreover, marketers should measure more than clicks. Useful indicators might include content engagement, qualified actions, educational resource use, healthcare professional interactions, or other metrics appropriate to the campaign.
Ultimately, a modern pharmaceutical marketing strategy should answer a simple question: Are we creating a more useful experience while meeting our responsibilities to patients, healthcare professionals, regulators, and the business?
Gaming can teach pharma how to learn faster. Healthcare must determine what is worth learning and where optimization should stop.
Conclusion
Tiffany William’s move from mobile gaming to Genentech offers a useful case study because the two industries could hardly carry more different responsibilities.
Yet gaming’s strongest disciplines translate surprisingly well. Rapid creative iteration, structured experimentation, behavioral analysis, segmentation, and continuous optimization can make pharmaceutical marketing more responsive and efficient.
However, pharma must reject mechanics designed to exploit vulnerability, manufacture urgency, or maximize engagement regardless of consequences.
The opportunity is not to make healthcare marketing feel like a game. Instead, it is to give pharma marketers a faster and more disciplined way to learn what genuinely serves their audiences.
Frequently Asked Questions
What is pharma performance marketing?
It uses campaign performance data to improve pharmaceutical marketing decisions, from media spending and creative testing to audience engagement. The approach can include testing, audience analysis, media optimization, creative iteration, and measurement of meaningful actions.
What can pharma marketers learn from gaming companies?
Gaming companies offer strong models for rapid testing, behavioral segmentation, creative experimentation, and continuous optimization. Pharma can adapt these practices while maintaining regulatory, privacy, and ethical safeguards.
Can pharma marketers use a fail-fast approach?
Yes, but only within appropriate boundaries. “Fail fast” should mean testing responsible hypotheses and learning quickly, not experimenting with unapproved or misleading promotional claims.
Which gaming marketing tactics should pharma avoid?
Pharma should be especially cautious about tactics that exploit fear, urgency, vulnerability, compulsive behavior, or reward loops to influence health decisions.
Why is continuous optimization important in pharma marketing?
Continuous optimization helps marketers learn from real audience behavior rather than relying only on assumptions. When used responsibly, it can improve relevance, reduce wasted media spending, and create more useful healthcare experiences.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
